Xerxine

Xerxine is a chlorinated-hydrocarbon solvent manufactured at Humboldt Chemical’s Xerxes plant, and its importance in the novel lies in the distance between an ordinary industrial product and the harm its production left behind. Used to clean oil from sheet metal, paint, and other materials, it becomes the center of an investigation into toxic exposure, workers’ illnesses, contested evidence, and corporate responsibility. Its effects surface not as one unmistakable accident but across years of work, medical records, and arguments over what could be proved.

Composition and Industrial Use

Xerxine was generally made by adding chlorine to ethylene gas. The resulting solvent had practical industrial uses, including cleaning oil from sheet metal and removing paint. The process of manufacturing it, however, released vapors into the air. The distinction between the product’s usefulness and the conditions of its production is crucial: the danger under investigation comes from workers breathing those vapors while Xerxine was being made.

When Humboldt Chemical began producing Xerxine in the 1950s, its lawyer later explained, knowledge of the chemical’s hazards was limited. The company was not described as having set out to kill its employees, but the plant did not initially control airborne chlorinated vapors carefully. The account places early exposure within a period when industrial practice and understanding of chemical risk had not yet caught up with the harm the substance could cause.

Exposure and Delayed Illness

The vapors were associated with damage to the liver, kidneys, and central nervous system. The novel connects this hazard to the long working lives of employees rather than to a single exposure or sudden event. Steve Ferraro had worked at Humboldt Chemical since 1959, and Pankowski since 1961. Both eventually became seriously ill and stopped working when their conditions prevented them from continuing; Ferraro had liver cancer, while Pankowski had aplastic anemia. They approached their lawyer in early 1983, after leaving the plant roughly two years earlier, and apparently had not been told that disability benefits might be available to them.

The medical records make the delay visible in a more precise way. Records for Louisa Djiak cover 1963 to 1982, while Ferraro’s cover 1957 to 1982. A specialist’s review identified about five hundred additional employees with records spanning 1955 to 1982. Across these files, changes in creatine, blood urea nitrogen, bilirubin, hematocrit, hemoglobin, and white blood count were consistent with the development of kidney, liver, and bone-marrow dysfunction. The records turn a diffuse history of exposure into a pattern that can be examined over time, while leaving the difficult question of individual causation open to challenge.

Louisa’s records show how far the damage could precede recognition. Her blood work indicated noticeable renal damage by 1967 and severe damage by 1969. She began experiencing diffuse symptoms around 1979, but interpreted them as possibly related to menopause and did not seek medical attention then. She first saw a physician in 1984, at her daughter’s insistence, and was diagnosed with chronic renal failure, which had since progressed to an acute stage. Other complications made her a poor candidate for a transplant. Ferraro’s records likewise traced changes over decades and ended with his death from aplastic anemia in 1983. In both cases, retrospective analysis connected blood changes with the known toxic properties of Xerxine, though the evidentiary and legal significance of that connection remained disputed.

Standards, Evidence, and Litigation

As concern about environmental pollution and workers’ health grew in the 1960s and 1970s, researchers including Irving Selikoff examined the effects of industrial chemicals. Xerxine could be toxic at relatively low concentrations. In response, Xerxes installed air scrubbers, sealed pipes more effectively, and reduced measured concentrations to federal standards. The account dates the U.S. Environmental Protection Agency’s Xerxine standard to the late 1970s and gives its limit as fifty parts per million.

That later standard did not resolve the claims arising from earlier years. Pankowski and Ferraro sued for indemnity payments they believed they were owed, arguing that their illnesses resulted from Xerxine exposure. Humboldt Chemical resisted the claim on two principal grounds: both men had other possible risk factors, including smoking and, in Pankowski’s case, heavy drinking, and their exposure predated the point when Xerxine’s toxicity was known. Their lawyer saw the company preparing to fight, but the case was lost. An appellate lawyer advised that there was not enough basis to proceed further.

The defeat exposes a gap between evidence compatible with a toxic cause and proof that a particular illness was work-related. When the case was later discussed, the distinction was stated bluntly: the blood data did not establish causality for the compensation claim. They had instead been used to project medical expenses and likely workforce turnover. Records capable of showing patterns of deterioration had been treated as tools for estimating the cost of sickness, not as proof that the workplace had caused it. In this way, the dispute concerns not only what the records contain, but also who uses them and what question they are allowed to answer.

Concealment and Consequences

The company’s defense relied partly on the timing of scientific and regulatory knowledge. In a later discussion, the argument is described as holding Humboldt responsible only for illness after 1975, when Xerxine’s toxicity was said to have been established by Ciba-Geigy. That date is distinct from the later federal exposure standard. The gap between them matters: a threshold for permitted concentrations does not erase earlier exposure, while a claim that the hazards were not yet known can limit an employer’s responsibility for it.

The blood records also change the meaning of insurance documents under investigation. Once the illnesses and their chronology are considered alongside the earlier compensation suit, the protagonist concludes that Art Jurshak’s report to Mariners Rest helped Humboldt conceal high rates of illness and death at Xerxes in seeking favorable insurance terms. She suspects the company’s official reports showed lower concentrations than those found in an analysis by SCRAP, though that remains her investigative conclusion at this point in the account. Xerxine thus sits at the intersection of workplace monitoring, employee benefits, and information supplied to an insurer.

The threat to Louisa makes those records and the people connected to them immediate stakes rather than a closed historical dispute. A caller says Louisa is at Xerxes, sedated, and threatens to leave her in the lagoons behind the plant if the police accompany the investigator. The warning links the chemical site to an effort to silence people who could speak about the past. Later, in confronting Gustav Humboldt, the investigator predicts that lawsuits over Xerxine will overwhelm the company, estimating claims of half a billion dollars and arguing that malicious intent will be provable. This is presented as her forecast during the confrontation, not as a settled legal outcome. Xerxine’s narrative significance lies in the way its harm accumulates: in bodies and blood measurements, in benefits not claimed, in litigation defeated by uncertainty, and in the struggle over whether the evidence will finally be heard.